NASDAQ:AKTX
Akari Therapeutics Plc Stock News
$1.17
-0.0438 (-3.62%)
At Close: Apr 19, 2024
Akari Therapeutics Appoints Rachelle Jacques as President and Chief Executive Officer
12:00pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
Industry veteran brings extensive experience in the development and commercialization of advanced biological therapies, including in the field of complement (C5) Industry veteran brings extensive e
NEW YORK and LONDON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune an
NEW YORK and LONDON, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced new data showing that clinical outcomes in U.S. Army trauma patients correlate with complement activation, and that nomacopan significantly improves survival from 30% to 80% in a clinically relevant preclinical model of traumatic hemorrhage. A full data set is available at https://doi.org/10.22541/au.164423459.98723938/v1
ADRs End Higher; Akari Therapeutics, British American Tobacco Trades Actively
03:20pm, Sunday, 13'th Feb 2022 MarketWatch
ADRs End Higher; Akari Therapeutics, British American Tobacco Trades Actively MarketWatch
Akari Therapeutics to Present at BIO CEO & Investor Conference
12:00pm, Friday, 11'th Feb 2022 GlobeNewswire Inc.
NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune an
Akari Therapeutics to Present at BIO CEO & Investor Conference
07:00am, Friday, 11'th Feb 2022
NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Akari says FDA agrees to use of new manufacturing process for nomacopan for trials
07:52pm, Wednesday, 19'th Jan 2022 Seeking Alpha
Akari Therapeutics <> said the U.S. Food and Drug Administration ((FDA)) agreed to the clinical use of nomacopan derived from a next generation manufacturing process.Nomacopan,…
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
07:00am, Tuesday, 04'th Jan 2022
NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and
Akari Therapeutics Stock (AKTX): Why The Price Fell
08:59am, Friday, 31'st Dec 2021
The stock price of Akari Therapeutics PLC (NASDAQ: AKTX) fell by 9.21% in the most recent trading session. This is why it happened.
Akari Therapeutics, Plc Announces $6.0 Million Registered Direct Offering
04:03pm, Thursday, 30'th Dec 2021 GlobeNewswire Inc.
NEW YORK and LONDON, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX) (“Akari” or the “Company”), a biopharmaceutical company focused on innovative therapeutics to tr
Akari Therapeutics (NASDAQ:AKTX) Stock Price Passes Above 50 Day Moving Average of $1.62
07:54am, Friday, 24'th Dec 2021 Dakota Financial News
Akari Therapeutics, Plc (NASDAQ:AKTX)s stock price crossed above its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $1.62 and traded as high as $1.64. Akari Therapeutics shares last traded at $1.54, with a volume of 75,065 shares traded. The company has a market cap of $73.30 million, []
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress
12:45pm, Friday, 03'rd Dec 2021 GlobeNewswire Inc.
NEW YORK and LONDON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune an
Akari Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Clinical Progress
12:45pm, Friday, 03'rd Dec 2021 Intrado Digital Media
NEW YORK and LONDON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced its financial results for the third quarter of 2021 and recent clinical progress.
Akari Therapeutics Presents New Data Revealing Potential Mechanism of Action Driving Serious Exacerbations Across Lung Disorders
01:30pm, Wednesday, 01'st Dec 2021 Intrado Digital Media
Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia Data suggest potential therapeutic role for nomacopan in exacerbations in severe lung conditions such as COPD and COVID pneumonia